EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

26 July 2024
EMA/CVMP/PhVWP/288284/2007-Rev.16
Committee for Veterinary Medicinal Products

Date for coming into effect: 1 October 2024
for use with VeDDRA EMA/CVMP/PhVWP/10418/2009-Rev.15 (EVVet implementation v20)

Guidance notes on the use of VeDDRA terminology for reporting suspected adverse events in animals and humans

1. Introduction

The purpose of these notes is to explain the principles of Veterinary Dictionary for Drug Related Affairs (VeDDRA) terminology and to provide advice about its use. The aim is to achieve a harmonised approach to the selection of VeDDRA terms.

VeDDRA has a four-level hierarchical structure as follows:

SOC – system organ class
HLT – high level term
PT – preferred term
LLT – low level term

The relationship between the SOC and the LLT is mono-axial i.e. a specific LLT is only available in one specific SOC. In cases where similar LLTs exist in other SOCs, an LLT contains a cross reference to the location of the other terms. In order to achieve medically relevant groupings for analysis of adverse events, the relation between PTs and LLTs covers two different concepts, allowing an LLT to be either a synonym or a sub-classification of a particular PT. For example, the PT 'Anaphylaxis' includes the LLTs 'Anaphylaxis' and 'Anaphylactoid reaction'. In VeDDRA, the terminologies in the SOC and the HLT are plural, with the PT and the LLT being in the singular (unless a particular term would not otherwise make medical sense). In addition, any PT term is available as an LLT too.

The selection of VeDDRA terms to describe an adverse event should be at LLT level. The LLT selected should be appropriate for the clinical signs described by the reporter, but also taking into consideration that this reflects the correct PT and SOC grouping. Analysis will normally be carried out at PT level. There are several situations where there could be more than one choice at LLT level, sometimes with different results at SOC level. Some of the more frequent situations are discussed below. It is not the intention to restrict the choices, but to encourage a standard approach so that the results of analysis will be consistent and valid.

If it is clear that a reported clinical sign occurred before administration of the product, or if it is known that it was due to the disease being treated or another specific cause (e.g. the reporter mentions

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

dietary ketoacidosis) it should not be coded using VeDDRA as this would not be classified as an adverse event related to a veterinary medicinal product. However, if there is any element of doubt the clinical sign should be coded in the usual way and this situation should subsequently be considered when analysing adverse event data.

In general, it is preferable to avoid coding the same or similar clinical signs multiple times (e.g. emesis and vomiting) unless the LLTs relate to different PTs as this may impact on subsequent analysis. However, there are some PTs e.g. gingival disorder, where multiple LLTs may need to be coded (e.g. gum bruising, gingival hyperplasia, gum pain and gingivitis) resulting in the PT being coded multiple times. Information on signs observed after re-challenge is useful for determining the causal association with the veterinary medicinal product administered.

It should also be noted that the VeDDRA terms list is deliberately kept as a non-exhaustive list where the focus is to cover the most commonly used terms and situations and to learn from practice through the feedback from users as part of the yearly revision exercise. In addition, the list is not intended to provide terms that would define a specific disease or syndrome.

Version history: in this version (EMA/CVMP/PhVWP/288284/2007-Rev.16[1]) relevant changes were made to the following section(s): 3 – Anaphylaxis and hypersensitivity reactions; and a new section was added 31 - Suspected infectious agent transmission, suspected reversal to virulence, suspected transmission of a vaccine strain, suspected recombination of a vaccine strain and suspected prolonged shedding of a vaccine strain.

2. Death

Death should always be recorded using VeDDRA. There are 8 choices at LLT level, all of which are described as 'Death' at PT level.

SOC	HLT	PT	LLT
Systemic disorders	Death	Death	Death
Systemic disorders	Death	Death	Death by euthanasia
Systemic disorders	Death	Death	Found dead
Systemic disorders	Death	Death	Increased culls
Systemic disorders	Death	Death	Increased mortality rate
Systemic disorders	Death	Death	Sudden death
Systemic disorders	Death	Death	Unexplained death
Systemic disorders	Death	Death	Unrelated death

This means that data extracted at PT level will not identify the relationship between the death and the adverse event so the case narrative must include all relevant details, including information as to how death occurred or why euthanasia was carried out if appropriate. The LLT 'Unrelated death' should be used only when there is clear evidence that the death was not associated with the adverse event e.g. road accidents. It should not be used when the owner elected for euthanasia for economic reasons or due to an underlying disease, in which case the LLT 'Death by euthanasia' should be used. The LLT

[1] for use with VeDDRA EMA/CVMP/PhVWP/10418/2009-Rev.15 (EVVet implementation v20)

'Sudden death' should be used when the fatality occurred unexpectedly e.g. without preceding clinical signs.

While there may be events involving multiple animals where it is appropriate to add both 'Death' and 'Death by euthanasia', it is important to be aware that the frequency of term selection in individual reports could influence the results of analysis, depending on the level at which analysis is carried out. Although the VICH standard enables the number of animals per VeDDRA term to be specified in individual reports, in cases where animals are euthanised (slaughtered) in high numbers, the LLT 'Increased culls' should be used.

See also section 24 Lack of efficacy for coding death in events following the use of euthanasia products. It should be noted that coding 'unrelated death' is not necessary for reports of lack of efficacy to endo-parasitic products where parasites are identified following routine slaughter or for residue reports where product residues are detected following routine slaughter.

3. Updated: Revision 16: Anaphylaxis and hypersensitivity reactions

The clinical signs of anaphylaxis or hypersensitivity reactions can vary according to the species and, in less severe cases, some of the signs are not obviously part of the syndrome, so it is sometimes a matter of opinion as to whether the reaction was anaphylaxis or hypersensitivity reaction. **If the reporter has described it as such**, it should be coded as anaphylaxis or hypersensitivity reaction using the appropriate LLT.

There are four and six terms, respectively, at LLT level, all of which are described as 'Anaphylaxis' and 'Hypersensitivity reaction' at PT level. Therefore, from the point of view of analysis, the choice of LLT term will make no difference.

SOC	HLT	PT	LLT
Immune system disorders	Allergic conditions	Anaphylaxis	Anaphylaxis
Immune system disorders	Allergic conditions	Anaphylaxis	Anaphylactic shock
Immune system disorders	Allergic conditions	Anaphylaxis	Anaphylactoid reaction
Immune system disorders	Allergic conditions	Anaphylaxis	Anaphylactic-type reaction
Immune system disorders	Allergic conditions	Hypersensitivity reaction	Allergic pruritus
Immune system disorders	Allergic conditions	Hypersensitivity reaction	Allergic skin reaction
Immune system disorders	Allergic conditions	Hypersensitivity reaction	Allergy NOS
Immune system disorders	Allergic conditions	Hypersensitivity reaction	Allergic reaction
Immune system disorders	Allergic conditions	Hypersensitivity reaction	Hypersensitivity NOS
Immune system disorders	Allergic conditions	Hypersensitivity reaction	Hypersensitivity reaction

[1] NOS = Not otherwise specified

If the reporter does not mention a clinical sign mapping to a LLT linked **to the PTs 'Anaphylaxis' or 'Hypersensitivity reaction'** but the case narrative matches with one of the following two definitions, then the reaction should be recorded as anaphylaxis or hypersensitivity reaction accordingly. Only code signs that occur after the product was administered. In all cases, use medical judgement for the final decision.

1. **ANAPHYLAXIS** is a severe allergic reaction that appears rapidly and is **life-threatening**. It is the most severe form of the Type 1 hypersensitivity mechanism. The clinical signs are very varied **but general systemic signs are always present**. The clinical picture is most often dominated by the presence of shock (acute systemic circulatory failure, altering the oxygenation and metabolism of various tissues and organs, which can lead to irreversible damage) with changes in mucous membrane colour (pale or bluish), changes in capillary refill time, tachycardia, a drop in systemic arterial pressure and a drop or loss of consciousness. Untreated anaphylactic reactions lead irrevocably to cardiovascular collapse.

Anaphylaxis should be coded when the following criteria are fulfilled:

Acute onset (up to 2 hours) of an illness with rapid progression of clinical signs AND including at least two of the following:

1) involvement of the skin and/or mucosal tissue (e.g. pruritus, oedema, facial swelling)
2) respiratory compromise (e.g. dyspnoea, bronchospasm, stridor, hypoxaemia)
3) clinical signs of cardiovascular compromise or end-organ dysfunction (e.g. hypotension, syncope, incontinence).

All the reported clinical signs should also be listed at LLT level.

2. **HYPERSENSITIVITY REACTION** is more moderate in intensity than anaphylaxis and **is not life-threatening.** Clinical signs are similar to those observed in anaphylaxis but are **clinically less intense and do not lead to cardiovascular collapse.**

Hypersensitivity should be coded when the following criteria are fulfilled:

Acute or non-acute (up to 72 hours) onset of clinical signs without respiratory compromise or clinical signs of cardiovascular or end-organ dysfunction and where three or more signs listed in Table 1, for the respective species, are reported. However, if the reaction is not considered to be a hypersensitivity reaction, hypersensitivity should not be coded and the justification should be described in the narrative.

Note: When one or two clinical signs are reported (e.g. vomiting and defecation, or sweating and coughing etc.) they should generally not be coded as hypersensitivity, except if other information in the case indicates hypersensitivity.

All the reported clinical signs should also be listed at LLT level.

Table 1. The main clinical signs of anaphylaxis or hypersensitivity reactions in individual species are listed below (NB this is not and exhaustive list)

Species	Clinical signs
Dog	Excitement, urticaria, pruritus, angioedema including facial oedema, eyelid oedema, lip oedema, Quincke's oedema, vomiting, defecation, dyspnoea, collapse, convulsions.
Cat	Pruritus, angioedema including facial oedema, eyelid oedema, lip oedema, Quincke's oedema, salivation, vomiting, dyspnoea, incoordination, collapse.
Horse	Shivering, sweating, incoordination, coughing, dyspnoea, diarrhoea, colic, collapse, urticaria and pruritis.
Cow and sheep	Urticaria, restlessness, pruritus, angioedema including eyelid oedema, mammary gland oedema or congestion and vulvar oedema or congestion, defecation, urination, coughing, dyspnoea, cyanosis, bloat, collapse.
Pig	Dyspnoea, cyanosis, pruritus, collapse, vomiting, diarrhoea.

Anaphylaxis and hypersensitivity reactions should be clearly differentiated from other systemic post-vaccine reactions and vagal shock.

'Vagal shock' is an LLT term which maps to 'circulatory shock' at the PT level. The clinical picture is composed of bradycardia, hypotension, cerebral hypoperfusion. Loss of consciousness may result from these alterations. The prognosis is not life-threatening, except for traumatic injury following a fall during syncope. Vagal malaise is not directly related to the veterinary medicinal product (VMP) but to the treatment environment (stress, pain, fear).

It is advised that 'Vagal shock' should only be coded if specifically mentioned by the original reporter. Marketing authorisation holders (MAHs) and national competent authorities (NCAs) should not code this term based on an interpretation of case narratives describing collapse-type events within seconds following product administration. 'Circulatory shock' or 'Circulatory collapse' is more appropriate terms to code these types of events. It is also important to differentiate between these events and those of suspected anaphylaxis or hypersensitivity reaction as described above.

'Neurological shock' (for example that associated with procaine penicillin administration) should be coded using the LLT 'shock' which maps to the PT 'circulatory shock'.

4. Local reactions

Adverse reactions which occur at the application, injection or implantation site should be described using LLT terms selected from the appropriate HLT under SOC 'Application site disorders'. This distinguishes them from non-specific local reactions which may be more difficult to assess for causality. For example:

SOC	HLT	PT	LLT
Application site disorders	Injection site reactions	Injection site hair change	Injection site alopecia

SOC	HLT	PT	LLT
Skin and appendages disorders	Hair follicle and sebaceous gland disorders	Alopecia	Alopecia local

5. Sarcoma

The LLT term 'Injection site sarcoma' should be used to describe sarcomas at injection sites. Other LLT terms used to describe sarcomas should be avoided because of the differences at PT level which would exclude them from analysis. For example:

SOC	HLT	PT	LLT
Neoplasia	Injection site neoplasms	Injection site sarcoma	Injection site sarcoma
Neoplasia	Application site neoplasms	Application site sarcoma	Application site sarcoma
Neoplasia	Skin and appendages neoplasms	Skin and/or appendage neoplasm NOS	Skin sarcoma NOS
Neoplasia	Connective tissue neoplasms	Fibrosarcoma	Skin fibrosarcoma

6. Dullness, lethargy, sleepiness, drowsiness, depression and malaise

Reporters often describe an animal which is ill in non-specific terms. The clinical signs which are reported should be viewed in the context of the overall reaction and it is important to be aware of the SOC in which an individual LLT is located. An exact match at LLT level could exaggerate the seriousness of the reaction. For example, dullness is frequently used to describe a mild, transient post-vaccinal reaction, but at LLT level the term is located in the SOC 'Neurological disorders' which does not reflect the true nature of the reaction. In this case it is important to record any additional reported clinical signs which give a more accurate picture of the overall reaction. If dullness is the only clinical sign which is reported, it may be necessary to obtain more details from the reporter.

Similarly, although the terms sleepiness and drowsiness may be used interchangeably by reporters in cases where there is either neurological impairment or general lethargy, from the overall picture of the report, it should be possible to select the most appropriate term from the list in the following table:

SOC	HLT	PT	LLT
Neurological disorders	Impaired consciousness	Impaired consciousness	Dullness
Neurological disorders	Impaired consciousness	Somnolence	Sleepiness – neurological disorder
Neurological disorders	Mental impairment	Cognitive disorder NOS	Drowsiness – neurological disorder

SOC	HLT	PT	LLT
Systemic disorders	General signs or symptoms	Lethargy	Lethargy (see also Central nervous system depression in Neurological)
Systemic disorders	General signs or symptoms	Lethargy	Depression
Systemic disorders	General signs or symptoms	Lethargy	Dull
Systemic disorders	General signs or symptoms	Lethargy	Drowsiness – systemic disorder
Systemic disorders	General signs or symptoms	Lethargy	Sleepiness – systemic disorder
Systemic disorders	General signs or symptoms	Lethargy	Mopey
Systemic disorders	General signs or symptoms	Malaise	Malaise
Systemic disorders	General signs or symptoms	Malaise	Off colour

7. Head tilt, balance problems and ataxia

Head tilt may be reported in association with adverse reactions which did not result from the administration of a product into the ear. The choice of this term at LLT level can be difficult as it may be due to either inner ear or neurological causes. The usual default would be to select the term 'Head tilt – ear disorder', but in situations where the overall picture is one of a neurological disturbance, the alternative 'Head tilt – neurological disorder' should be selected. Conversely, balance problems may be vestibular in origin, so when they are reported in association with a possible ear disorder, a term from the SOC 'Ear and labyrinth disorders' should be included with terms from the SOC 'Neurological disorders'.

SOC	HLT	PT	LLT
Ear and labyrinth disorders	Internal ear disorders	Internal ear disorder	Head tilt – ear disorder
Ear and labyrinth disorders	Internal ear disorders	Internal ear disorder	Internal ear disorder
Ear and labyrinth disorders	Internal ear disorders	Internal ear disorder	Tumbling circling disease (see also ataxia in Neurological)
Ear and labyrinth disorders	Internal ear disorders	Internal ear disorder	Vestibular disorder NOS

SOC	HLT	PT	LLT
Neurological disorders	Central nervous system disorders	Central nervous system disorder NOS	Head tilt – neurological disorder
Neurological disorders	Coordination and balance signs	Ataxia	Balance impaired
Neurological disorders	Coordination and balance signs	Ataxia	Balance problem
Neurological disorders	Coordination and balance signs	Ataxia	Equilibrium disorder
Neurological disorders	Coordination and balance signs	Ataxia	Lack of coordination (see also Ear – vestibular disorder)

8. Pain and discomfort

Animals are sometimes reported as being in pain or showing signs of pain when touched. This could reflect a systemic condition, in which case the choice of one of the following LLT terms in the SOC 'Systemic disorders' would be appropriate. However, an exaggerated response could be a sign of a different syndrome. A separate PT exists for cases where discomfort, as opposed to overt pain, is reported.

SOC	HLT	PT	LLT
Systemic disorders	General signs or symptoms	General pain	General pain (see other SOCs for specific pain)
Systemic disorders	General signs or symptoms	General pain	Pain NOS
Systemic disorders	General signs or symptoms	Localised pain NOS	Localised pain NOS (see other SOCs for specific pain)
Systemic disorders	General signs or symptoms	Discomfort NOS	Discomfort NOS
Systemic disorders	General signs or symptoms	Discomfort NOS	Uncomfortable
Neurological disorders	Sensory abnormalities	Hyperaesthesia	Hypersensitivity to pain

9. Distress

Distress is a term often used by reporters to describe an animal which is not behaving normally, yet the reaction is rarely associated with a behavioural disorder. In VeDDRA the term is located in this SOC, so in cases in which it is the only reported sign and the overall picture is not clear, it may be necessary to seek advice from the Qualified Person for Pharmacovigilance (QPPV) or the NCA in order to achieve consistency in the recording of this term.

SOC	HLT	PT	LLT
Behavioural disorders	Other behavioural disorders	Anxiety	Distress

Stress is a state of mental or emotional strain or tension resulting from adverse or demanding circumstances and is often reported by animal owners. Animals show stress by behaving differently than usual and this should be coded by 'Behavioural disorder NOS'.

10. Collapse

There are three LLT terms available in VeDDRA to describe collapse, each of which is located in a different SOC (see below). It is important to ensure that the choice of term at LLT level is appropriate in the context of the overall reaction. None of the LLT terms describing collapse are in the SOC 'Immune system disorders', yet this clinical sign is often reported in association with anaphylaxis (see section 3).

SOC	HLT	PT	LLT
Cardio-vascular system	Circulatory disorders	Circulatory shock	Circulatory collapse (see also Neurological and Systemic disorders)
Neurological disorders	Impaired consciousness	Loss of consciousness	Collapse (see also Cardio-vascular and Systemic disorders)
Systemic disorders	General signs or symptoms	Collapse NOS	Collapse NOS (see also Cardio-vascular and Neurological disorders)

11. Reduced urination

Failure to urinate may be due to either a physiological or anatomical problem within the urinary tract itself or else a more psychological or behavioural response (e.g. to distress or fear). A complete absence of urination should be coded as 'Anuria' unless there is evidence of behavioural dysfunction in which case the term 'Not urinating' can be selected.

Note also the terms in the PTs 'Dysuria' and 'Stranguria' which represent difficulty or pain in urinating respectively. Although the LLT 'Pollakiuria' describes abnormally frequent attempts at urination it appears in the 'Dysuria' PT due to the low volume of urine produced on each attempt.

SOC	HLT	PT	LLT
Behavioural disorders	Other behavioural disorders	Inappropriate urination	Not urinating
Renal and urinary disorders	Renal disorders	Anuria	Anuria
Renal and urinary disorders	Urinary tract disorders	Dysuria	Difficulty in micturition
Renal and urinary disorders	Urinary bladder disorders	Polyuria/pollakiuria	Pollakiuria
Renal and urinary disorders	Urinary tract disorders	Stranguria	Painful urination

12. Recumbency, prostration and self-auscultation position

Recumbency can be the result of several different types of adverse reaction and the term is in the SOC 'Systemic disorders', under the PT 'Recumbency'. Some abnormal postures relating to recumbent animals can also be found as LLTs within this PT, including 'Prostration' (a specific body position where the animal is lying completely flat out) and 'Self-auscultation position' (when the animal's neck is bent so that the head lies against the chest).

In situations where the reason for recumbency could be neurological, it would be advisable to select at least one other LLT term from the SOC 'Neurological disorders' (see examples below) in order to capture this information.

SOC	HLT	PT	LLT
Systemic disorders	General signs or symptoms	Recumbency	Abnormal posture
Systemic disorders	General signs or symptoms	Recumbency	Lateral recumbency
Systemic disorders	General signs or symptoms	Recumbency	Prostration
Systemic disorders	General signs or symptoms	Recumbency	Recumbency
Systemic disorders	General signs or symptoms	Recumbency	Self auscultation position
Systemic disorders	General signs or symptoms	Recumbency	Unable to rise
Neurological disorders	Paralytic and paretic disorders	Paralysis	Hind limb paralysis
Neurological disorders	Paralytic and paretic disorders	Paresis	Paresis

SOC	HLT	PT	LLT
Neurological disorders	Coordination and balance signs	Ataxia	Unable to stand

13. Reluctance to move

Non-specific changes in an animal's behaviour, such as inertia, are difficult to record accurately if other clinical signs are not reported. There are several choices at LLT level (see below). In cases where the situation is unclear, and few details are reported it would be advisable to select a term in the PT 'Lethargy' in order to indicate the generalised systemic nature of the reaction. This could be important in a situation where an animal is showing some signs of mobility but not the full range of movement. In such cases a single term from the SOC 'Musculoskeletal disorders' or the SOC 'Neurological disorders' may not be an accurate description of the reaction.

SOC	HLT	PT	LLT
Systemic disorders	General signs or symptoms	Reluctant to move	Reluctant to move
Musculoskeletal disorders	Musculoskeletal disorders	Musculoskeletal disorder NOS	Limb weakness
Neurological disorders	Coordination and balance signs	Ataxia	Walking difficulty

14. Anorexia

Anorexia in humans may be a symptom of a psychological disturbance, in which case the LLT 'Eating disorder NOS' in the SOC 'Psychological disorders' should be used. This term should be used only for human reports.

SOC	HLT	PT	LLT
Psychological disorders	Eating disorders	Eating disorder NOS	Eating disorder NOS (see Systemic for anorexia etc)

Anorexia is frequently used by reporters to describe loss of appetite as a clinical sign in many different types of adverse reaction in animals and humans. In this situation a term from the PT 'Anorexia' in the SOC 'Systemic disorders' should be selected (see examples below).

SOC	HLT	PT	LLT
Systemic disorders	General signs or symptoms	Anorexia	Anorexia
Systemic disorders	General signs or symptoms	Anorexia	Decreased appetite
Systemic disorders	General signs or symptoms	Anorexia	Reduced food intake

15. Hyperactivity

In animals, hyperactivity is regarded as a behavioural disorder in VeDDRA. This term should be used only for animal reports.

SOC	HLT	PT	LLT
Behavioural disorders	Other behavioural disorders	Hyperactivity	Hyperactivity

Hyperactivity may also be reported in a human as a symptom of abnormal behaviour, in which case the LLT 'Hyperactive' in the SOC 'Psychological disorders' should be used. This term should be used only for human reports.

SOC	HLT	PT	LLT
Psychological disorders	Personality and mood disorders	Abnormal behaviour	Hyperactive

16. Foaming at the mouth

There are two LLT terms available in VeDDRA to describe the drooling of non-bloody fluid from the mouth of an animal which is often described by reporters as 'foaming at the mouth'. An additional term exists to describe incidents when bloody foam is seen in both the mouth and nose.

SOC	HLT	PT	LLT
Digestive tract disorders	Oral cavity disorders	Hypersalivation	Foaming at the mouth
Respiratory tract disorders	Respiratory tract disorders	Foam in respiratory tract	Foam in the mouth
Respiratory tract disorders	Respiratory tract disorders	Foam in respiratory tract	Bloody foam in mouth and nose

As the terms are in different SOCs, their selection at LLT level could be critical in ensuring that the clinical syndrome described by the reporter is recorded correctly. It is advisable to include additional LLT terms from the relevant SOCs whenever possible, so that the adverse reaction is characterised accurately. It should also be remembered that 'foaming at the mouth' can be associated with neurological disorders such as muscle tremors, convulsions and tetany, although in these cases it is unlikely to be the sole clinical sign which is reported.

17. Induced vomiting

Vomiting may be induced in order to treat a condition. In such cases it would not be appropriate to record vomiting as a clinical sign involved in the adverse reaction if an emetic had been administered.

18. Panting, stridor and rale

'Panting' describes a fast and shallow open-mouthed breathing pattern observed commonly, but not exclusively, in dogs in response to both physiological and psychological disturbances. Since VeDDRA

terms can only appear under one SOC, if it is considered that a report of panting indicates some form of anxiety, this should be coded separately.

'Stridor' is an abnormal, high-pitched sound produced by turbulent airflow through a partially obstructed airway within the upper respiratory tract. Its aetiology is therefore quite different from 'Rale', an abnormal rattling sound from within the chest and can be either bronchial or tracheal. This is reflected in their coding where cross referencing has also been provided.

SOC	HLT	PT	LLT
Respiratory tract disorders	Bronchial and lung disorders	Tachypnoea	Panting
Respiratory tract disorders	Bronchial and lung disorders	Rale	Bronchial rale
Respiratory tract disorders	Bronchial and lung disorders	Rale	Harsh lung sounds
Respiratory tract disorders	Bronchial and lung disorders	Rale	Increased lung sounds
Respiratory tract disorders	Tracheal and laryngeal disorders	Tracheal and laryngeal disorder NOS	Tracheal rales
Respiratory tract disorders	Respiratory tract disorders	Respiratory tract disorder NOS	Stridor (Upper respiratory; for lower respiratory see also Bronchial rale)

19. Embolism and thromboembolism

Since emboli are generally formed in the heart, this LLT is found under the PT 'Cardiac embolism'. Conversely where emboli lodge in the lung this is recorded under the SOC 'Respiratory tract disorders'.

SOC	HLT	PT	LLT
Cardio-vascular system disorders	Cardiac/heart disorders	Cardiac embolism	Cardiac embolism
Cardio-vascular system disorders	Cardiac/heart disorders	Cardiac embolism	Embolism
Respiratory tract disorders	Bronchial and lung disorders	Pulmonary thromboembolism	Pulmonary thromboembolism

20. Metastatic neoplasia and secondary malignancy

Secondary malignancies are cancers caused by treatment with radiation or chemotherapy. They are unrelated to the first cancer that was treated and may occur months or even years after initial treatment. They should not, therefore, be confused with metastatic tumours which are related to the primary tumour and are the result of local, haematogenous or lymphatic spread of malignant cells from the primary tumour. Consequently, these terms are coded differently.

SOC	HLT	PT	LLT
Neoplasia	Neoplasia NOS	Metastatic neoplasia	Metastatic neoplasia
Neoplasia	Neoplasia NOS	Metastatic neoplasia	Metastatic tumour
Neoplasia	Neoplasia NOS	Neoplasia NOS	Secondary malignancy

21. Prolonged anaesthesia, premature anaesthesia recovery and rough recovery

Although 'prolonged anaesthesia' and 'premature anaesthesia recovery' might on the face of it be considered simply the opposite of each other they are in quite different SOCs, as indicated below. A separate PT exists for 'Rough recovery' and therefore this should also be coded when applicable.

SOC	HLT	PT	LLT
Neurological disorders	Impaired consciousness	Sedation	Prolonged anaesthesia
Systemic disorders	General signs or symptoms	Premature anaesthesia recovery	Premature anaesthesia recovery
Systemic disorders	General signs or symptoms	Rough recovery	Rough recovery

22. Investigations and diagnostic test results

The principles of VeDDRA terminology were established to describe clinical signs or other easily detectable clinical information. However, as the availability of diagnostic equipment and services to veterinary practices continues to develop, further terms were requested and a SOC was created to group all these investigation results in one place and a selection is provided in the table below. If the appropriate term is not available in VeDDRA, one of the following terms should be selected and details of the test should be provided in the narrative.

SOC	HLT	PT	LLT
Investigation	Abnormal cytology	Abnormal cytology	Abnormal cytology
Investigations	Abnormal imaging	Abnormal radiograph finding	Abnormal radiograph finding
Investigations	Abnormal imaging	Abnormal ultrasound finding	Abnormal ultrasound finding
Investigations	Abnormal physical examination	Abnormal rectal palpation	Abnormal rectal palpation
[…]	[…]	[…]	[…]
Investigations	Other abnormal test result NOS	Other abnormal test result NOS	Other abnormal test result NOS

SOC	HLT	PT	LLT
Investigations	Abnormal histology	Abnormal histology	Abnormal histology

It should be noted that the PT 'high adrenocorticotropic (ACTH) hormone' should be used only to code cases where the levels of this hormone have been measured, for example in the investigation of pituitary pars intermedia dysfunction. This term maps to 'pituitary investigations' at HLT. Signs relating to adrenal gland investigations (such as Abnormal adrenocorticotropic hormone (ACTH) stimulation test) should be coded as such under the HLT 'adrenal investigations'.

23. Necropsy

Reports which include results from necropsy (or autopsy) should follow the principle that all abnormal necropsy findings which have a plausible temporal association to product administration should be coded using the appropriate LLT unless findings are known to be associated with the disease being treated.

Pathologic findings which indicate prior or ongoing health issues or other incidental findings should be mentioned in the case narrative only if they are particularly relevant (e.g. due to pre-existing pathology the animal was particularly prone to the adverse event).

When a necropsy (or autopsy) report, or its findings, are reported for a case the LLT 'Necropsy performed' should be coded to indicate the case includes necropsy findings.

The list of VeDDRA terms in a report should never be limited to the LLTs 'Death' and 'Necropsy performed' only.

24. Lack of efficacy

If the reported adverse event clearly relates solely to lack of expected efficacy, the term 'lack of efficacy' should be used in isolation without any of the observed signs indicative of the lack of efficacy. For any reports resulting in fatalities, 'death' should also be coded. The term 'uncoded sign' should never be used to code for the disease being treated.

If the report describes clinical signs relating to both safety and lack of expected efficacy or if there is any doubt as to what type of case it is (e.g. if clinical signs appear to have worsened following treatment) it should be submitted as one combined report with all signs being coded including 'Lack of efficacy'.

In order to provide further coding detail for multi-indication products e.g. combination antiparasitic products and multivalent vaccines, additional LLTs have been created, all situated within the PT 'Lack of efficacy'.

Lack of efficacy LLTs are now grouped together using the following system to aid user coding: Lack of efficacy (bacteria), Lack of efficacy (ectoparasite), Lack of efficacy (endoparasite), Lack of efficacy (fungi), Lack of efficacy (mycoplasma), Lack of efficacy (protozoa) and Lack of efficacy (virus).

Lack of expected efficacy following the use of euthanasia products should be coded using only the VeDDRA low level terms 'lack of efficacy' and 'unrelated death' (as the death was unrelated to the adverse event 'lack of efficacy'). No other clinical signs observed should be coded using VeDDRA. In all cases, however, such reports are considered serious adverse events and should be reported accordingly.

25. Uncoded sign

The LLT 'Uncoded sign' should ONLY be used when there is no existing VeDDRA term to code the clinical sign(s) observed. Further detail relating to the clinical sign should be explained in the narrative of the adverse event report. Where appropriate, a proposal for a new VeDDRA term should be submitted to the VeDDRA sub-group for consideration at their next annual review using the templates available in the call for comments.

26. Product defects

SOC	HLT	PT	LLT
Other event	Other event	Counterfeit product	Confirmed counterfeit product
Other event	Other event	Counterfeit product	Suspect counterfeit product
Product defects	Product defect NOS	Product defect NOS	Product defect NOS

'Product defect NOS' should be used when an adverse event is reported in relation to any of the following situations:

a) If the veterinary medicinal product (i.e. finished dosage form e.g. tablet, capsule, solution) is suspected to be abnormal (e.g. murky instead of clear, unknown sediments, abnormal viscosity, abnormal smell, potency issues, contamination, etc.);

b) In circumstances where there is another defect which is not related to a product quality issue (e.g. defective packaging, defective primary containers, issues with labelling, missing tablets, underfilling, etc.); or

c) Administration device issues that relate to a defect (e.g. missing or broken, incorrect calibration, calibration illegible). If, however there are problems with the use of the administration device (e.g. device difficult to use) please refer to specific terms under SOC 'Medication and product use errors'.

27. Decubitus and decubitus ulceration

The LLT term 'decubitus' which maps to the PT term 'recumbency' describes the body position of the animal. Ulceration (or decubitus ulceration as it is sometimes referred) due to prolonged recumbency should be coded using the term 'skin ulceration'.

28. Oral obstruction

The LLT term 'oral obstruction' which maps to the PT oral cavity disorders NOS should be used for reports where the chew gets stuck between the teeth or in the mouth of the animal. It should only be reported together with other signs such as e.g. hypersalivation or dysphagia.

29. Medication and product use errors

The terms in this SOC shall aid the identification and coding of 'special situations', some of which are described in the Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Collection and recording of suspected adverse events for veterinary medicinal products (EMA/306663/2021).

SOC	HLT	PT	LLT
Medication and product use errors	Accidental exposure to product	Accidental exposure	Accidental exposure
Medication and product use errors	Administration errors and issues	Administration error NOS	Administration error NOS
Medication and product use errors	Administration errors and issues	Overdose	Overdose
Medication and product use errors	Administration errors and issues	Underdose	Underdose
Medication and product use errors	Device use issues	Device use issues NOS	Device use issues NOS
Medication and product use errors	Intentional misuse	Intentional misuse	Intentional misuse
Medication and product use errors	Medication and product use errors NOS	Medication error NOS	Medication error NOS
Medication and product use errors	Prescribing errors and issues	Prescribing error	Prescribing error

In adverse event reports where a medication error occurred but no specific information is available or if a specific error is reported but no suitable LLT is available the PT/LLT level 'Medication error NOS' is recommended.

The PT/LLT 'Administration error NOS' shall be used when a wrong administration route was used by mistake/unintentionally. This should reflect unintentional use to differentiate from regular 'off-label use' cases where the person administrating the veterinary medicinal product has chosen a different administration route intentionally (i.e. those cases would only be flagged as 'off-label use' and 'wrong administration route' to distinguish from these 'unintentional cases' that will also have a VeDDRA code related to the medication error.

Intentional misuse is defined as deliberate use of a veterinary medicinal product or a medicinal product for human use in animals for a purpose not consistent with applicable legal or medical guidance whether or not clinical signs are observed. Misuse is also intentional use of a veterinary medicinal product in humans, unless permitted by legal provision, whether or not clinical signs are observed. Misuse may be instigated by a veterinarian, other animal healthcare professional, animal owner or other individual.

Accidental exposure should be used to code events with unintended exposure to a veterinary e.g. exposure via a treated animal or in cases of medication error, such as human exposure via accidental ingestion of veterinary medicinal product.

Where problems related to the handling of a product device (by the user) or with the acceptance of the device (by the animal) reported, the PT/LLT 'device use issues NOS' is recommended. If the problem with device use is due to a product defect, then the VeDDRA HLT/PT/LLT 'product defect NOS' should be used instead.

30. Parent – offspring events

The LLTs in PT 'Parent-offspring event' shall aid the identification and coding of special scenarios as described in the Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Collection and recording of suspected adverse events for veterinary medicinal products (EMA/306663/2021), 'Suspected adverse event reports for offspring exposed through a parent'.

These terms must be used in addition to other relevant VeDDRA terms (e.g. clinical signs, product defect) of the reacting animals. The list of VeDDRA terms in a report should never be limited to one of these terms.

SOC	**HLT**	**PT**	**LLT**
Other event	Other event	Parent-offspring event	Parent-offspring event
Other event	Other event	Parent-offspring event	Father and offspring event
Other event	Other event	Parent-offspring event	Mother and offspring event
Other event	Other event	Parent-offspring event	Offspring-only event

- LLT 'Parent-offspring event' should be used in adverse events where an unidentified parent was treated and it is suspected that the treated parent and offspring are affected by this treatment.
- LLT 'Mother and offspring event' should be used in adverse events where the mother was treated and it is suspected that mother and offspring are affected by this treatment.
- LLT 'Father and offspring event' should be used in adverse events where the father was treated and it is suspected that father and offspring are affected by this treatment.
- LLT 'Offspring-only event' should be used in adverse events where one or both parents were treated and it is suspected that only the offspring is/are affected by this treatment.

Important scenarios to consider:

- In case of adverse events observed with abortion, none of the parent-offspring event VeDDRA terms should be used.
- In cases of LEE reported for veterinary medicinal products (VMPs) applied to parent animal(s) and which are indicated to reduce foetal mortality, abortion or transmission of a pathogen to the offspring, the "lack of efficacy" applies to the parent and does not refer to the offspring, as the VMP should have been effective in the parent animal(s). In this case none of the parent-offspring event VeDDRA terms should be used.
- In cases of adverse events observed with stillbirth, the relevant parent-offspring event VeDDRA term should be used, in addition to all other relevant VeDDRA terms and, at the very least, the VeDDRA term "Stillbirth".

In cases of LEE reported for VMPs applied to parent animal(s) and ***which are indicated to protect the offspring*** *(for example: vaccines that are administered to the parent to protect the offspring by transferring specific antibodies via the colostrum)* and insufficient efficacy can be assumed in the offspring, the 'offspring only event' VeDDRA term should be used in addition to the relevant lack of efficacy VeDDRA term. The treated animal(s) still refers to the parent animal(s).

31. New: Revision 16: Suspected infectious agent transmission, suspected reversal to virulence, suspected transmission of a vaccine strain, suspected recombination of a vaccine strain and suspected prolonged shedding of a vaccine strain

If a report of **suspected transmission of an infectious agent** via a VMP (e.g. contamination with a pathogen, insufficient inactivation etc.) is received, select the LLT 'Suspected infectious agent transmission'. Medical judgment should be used if the reporter does not explicitly state transmission of an infectious agent via a VMP but this could be implied by other data within the report.

In contrast to this term, **suspected reversal to virulence** concerns attenuated live vaccines, where clinical signs after administration indicate that the vaccine strain has reverted to be more pathogenic.

The term **suspected transmission of a vaccine strain** should be used in cases where unvaccinated animals acquire the vaccine strain, with or without signs of disease.

The term **suspected recombination of a vaccine strain** is related to cases in which a vaccine strain is suspected of recombination with another field strain and/or vaccine strain, as a specific genetic event, with or without signs of disease.

The term **suspected prolonged shedding of a vaccine strain** could be used in case of prolonged shedding or dissemination of a vaccine strain for a longer time-frame that that known for the vaccine strain i.e. as specified in the in the marketing authorisation application, European public assessment report (EPAR) or the product information (PI).

Medical judgment should be used to differentiate between these terms.

Some examples as aid have been provided below:

SOC	HLT	PT	LLT
Systemic disorders	General signs or symptoms	Suspected infectious agent transmission	Suspected infectious agent transmission
Systemic disorders	General signs or symptoms	Suspected reversal to virulence	Suspected reversal to virulence
Systemic disorders	General signs or symptoms	Suspected transmission of vaccine strain	Suspected transmission of vaccine strain
Systemic disorders	General signs or symptoms	Suspected recombination of a vaccine strain	Suspected recombination of a vaccine strain
Systemic disorders	General signs or symptoms	Suspected prolonged shedding of a vaccine strain	Suspected prolonged shedding of a vaccine strain

Examples:

Reported	LLT selected
A dog was treated with a nasal spray product and later developed a severe acute nasal infection with Bacteria X. Cultures of unopened containers of the nasal spray grew Bacteria X.	Suspected infectious agent transmission
In a swine herd, piglets aged 3-18 weeks were vaccinated with a live attenuated vaccine virus. There were no associated reproductive problems in the herd at that time. 1-2 months later, there was an increased number of abortions and weak or stillborn piglets. Virus was isolated from weak or stillborn piglets and was further characterised as having originated from the live vaccine virus, causing suspicion of the live attenuated vaccine virus to have changed genetically and reverted to virulence under field conditions and started to spread within the herd, including to non-vaccinated sows.	Suspected reversal to virulence
In a sheep flock vaccinated with *B. melitensis* Rev 1 live vaccine (in 3-6 months aged), the Rev 1 vaccine strain is detected from female dogs on the same farm.	Suspected transmission of a vaccine strain
Several possible scenarios: a) Sows vaccinated with a PRRS vaccine ABC prior to farrowing – clinical signs in piglets. XYZ PRRS vaccine virus found with 98% homology; XYZ PRRS vaccine was never used on the farm; b) Sows vaccinated with PRRS vaccine ABC; recurrent respiratory signs in nursery/fattening pigs with 99% homology to the respective ABC PRRS vaccine strain; c) Sows vaccinated with PRRS vaccine ABC. Clinical signs: premature births, mummification and stillborn piglets. Positive for recombinant virus with ABC PRRS vaccine strain ORF genome homology (99.5%).	Suspected recombination of vaccine strain
In a poultry flock vaccinated with a live Salmonella vaccine, the vaccine strain is identified in unvaccinated animals and/or fomites (i.e. litter) and/or foodstuffs (eggs) for a longer period that that stated in the product information.	Suspected prolonged shedding of vaccine strain